Clinical trials: Secondary Bone Cancer
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
- Trial name
- NCT01419717
- Testing
- Denosumab
- Where
- 64 sites in Argentina, Austria and 17 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Breast Cancer, Hypercalcemia of Malignancy
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
- Trial name
- NCT00060138
- Testing
- monoclonal antibody CAL, zoledronic acid
- Where
- United States
- Sponsor
- Chugai Pharmaceutical
Breast Cancer, Prostate Cancer
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
This is an open-label exploratory study of CTAP101 Capsules in patients with bone metastases arising from either breast or prostate cancer, who are taking anti-resorptive therapy.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia
- Trial name
- NCT02274623
- Testing
- CTAP101 Capsules
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- OPKO Health, Inc.
Metastatic Breast Cancer in the Spine
ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES
ZetaMet™ is indicated for patients with destructive, lytic lesions due to metastatic breast cancer to bone, with or without involvement of other sites, with at least one metastatic lesion located in a vertebral body of the spine…
- Trial name
- ZGMBC (NCT05280067)
- Testing
- ZetaMet™ (ZetaFuse™ Bone Graft)
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Zetagen Therapeutics, Inc
Bone Metastases From Solid Tumors
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.
- Trial name
- NCT04630522
- Testing
- Drug: JMT103- 120 mg SC Q4W, Drug: JMT103- 120 mg SC Q8W, Drug: JMT103- 180 mg SC Q8W
- Where
- China
- Volunteers
- 295 people
- Sponsor
- Shanghai JMT-Bio Inc.
Leukemia
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone…
- Trial name
- NCT00454168
- Testing
- PR1 leukemia peptide vaccine, sargramostim
- Where
- 15 sites in United States
- Volunteers
- 244 people
- Sponsor
- The Vaccine Company
Pain, Bone Neoplasm
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
This single arm study will assess the efficacy of loading doses of intravenous Bondronat in reducing pain in patients with breast cancer and metastatic bone disease experiencing moderate to severe bone pain.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00478270
- Testing
- ibandronate [Bondronat]
- Where
- 6 sites in Greece
- Sponsor
- Hoffmann-La Roche
Fever, Sweats, and Hot Flashes, Infection
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood disease or cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00886496
- Testing
- recombinant human mannose-binding lectin
- Where
- 3 sites in United States
- Sponsor
- Enzon Pharmaceuticals, Inc.
Breast Cancer
An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)
This open non-randomized, single-arm, multicenter, observational study is designed to evaluate the correlation between bone turnover markers and the response to treatment in patients with breast cancer and bone metastases.
- Trial name
- NCT02553850
- Where
- 19 sites in Hungary
- Volunteers
- 442 people
- Sponsor
- Hoffmann-La Roche
Neoplasm Metastasis
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.
- Trial name
- NCT00434317
- Testing
- Zoledronic acid
- Where
- 4 sites in Hungary
- Volunteers
- 80 people
- Sponsor
- Novartis
Bone Neoplasms
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events…
- Trial name
- NCT00434447
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the…
- Trial name
- NCT01499043
- Testing
- PLX3397
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases
This is an open labelled study. It was designed to evaluate the safety of multiple-dosing of TK006 in patients with breast cancer-related bone metastases.
- Trial name
- NCT03487055
- Testing
- TK006
- Volunteers
- 30 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
The purpose of this study was to explore the safety and tolerability of enzalutamide in combination with abiraterone acetate plus prednisone.
- Trial name
- NCT01650194
- Testing
- enzalutamide, abiraterone acetate, prednisone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Patients With Bone Metastases
PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases
To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection…
- Trial name
- NCT06380881
- Testing
- SHR-2017
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors, Sarcoma
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib. This is a Phase 1, open-label, dose-escalation, dose-expansion, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum…
- Conditions
- Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT03604783
- Testing
- TP-1287
- Where
- 10 sites in United States
- Volunteers
- 74 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bone Cancer, Bone Tumor
A Dose Finding Study to Treat Bone Tumor(s)
To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects…
- Conditions
- Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone
- Trial name
- NCT06008483
- Testing
- 153-Sm-DOTMP (Samarium-153-DOTMP)
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- QSAM Therapeutics, Inc.
Cancer Prostate
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
The objective of the study is to investigate whether blood markers can be used to predict the development of bone metastases and to assess the efficacy and safety of zoledronic acid in cancer treatment induced bone loss.
- Trial name
- NCT00172055
- Testing
- Zoledronic acid
- Where
- 19 sites in Belgium
- Volunteers
- 218 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00070538
- Testing
- cytarabine, laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals